ReviewTranslational cancer research2020
Adrenocortical carcinoma: a literature review.
Review in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 27 citations in OpenAlex.
- Phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: adrenocortical carcinoma cohort.Journal for immunotherapy of cancer · 2024Trial
- Cerebral Metastasis in a Fatal Adrenocortical Carcinoma: A Rare Presentation of an Aggressive Tumor.Diagnostics (Basel, Switzerland) · 2026Article
- Locally advanced adrenal tumor invading the stomach revealed by upper gastrointestinal hemorrhage: a case report.International journal of surgery case reports · 2026Article
- Pitfalls of Adrenal Washout on CT in the Adult Population: A Pictorial Review.Diagnostics (Basel, Switzerland) · 2026Review
- Tumor stage-dependent expression of autophagy proteins in adrenocortical carcinoma.Frontiers in endocrinology · 2026Article
- Role of Palliative Bronchial Stenting in Endobronchial Metastasis: An Atypical Case of Metastatic Adrenocortical Carcinoma in a Young Patient.Clinical case reports · 2025Article
- Ki-67 as a Predictor of Metastasis in Adrenocortical Carcinoma: Artificial Intelligence Insights from Retrospective Imaging Data.Journal of clinical medicine · 2025Article
- Bilateral adrenal tumors presenting with Cushing syndrome in the setting of horseshoe kidney: surgical and urological considerations (case report).The Pan African medical journal · 2025Article
- Adrenocortical Carcinoma: A Challenging Diagnosis.Cureus · 2024Article
- Adrenocortical Carcinomas: Molecular Pathogenesis, Treatment Options, and Emerging Immunotherapy and Targeted Therapy Approaches.The oncologist · 2024Review
- Adrenal cyst presenting with clinical features of a pheochromocytoma.Radiology case reports · 2024Article
- Construction of a novel clinical nomogram to predict cancer-specific survival in patients with primary malignant adrenal tumors: a large population-based retrospective study.Frontiers in medicine · 2023Article
- Interplay between Immune Cell Infiltration and Tumor Histological Subtype: A Case of Adrenocortical Cancer.Cancers · 2022Article
- Identification of potential core genes and miRNAs in pediatric ACCIntractable & rare diseases research · 2022Article
- Prediction of Adrenocortical Carcinoma Relapse and Prognosis with a Set of Novel Multigene Panels.Cancers · 2022Article
- Distinguishing between metastatic and benign adrenal masses in patients with extra-adrenal malignancies.Frontiers in endocrinology · 2022Article
- The Multifaceted Nature of Nucleobindin-2 in Carcinogenesis.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adrenocortical carcinoma (ACC) is reported to be present in 3-10% of the population with most tumors presenting as benign tumors. Most cases of ACC are a sporadic accumulation of mutations over time. However, studies show a predisposition to various genetic mutations may contribute. Research over the last couple of decades has elucidated causes of ACC to be driven by several molecular changes that include inactivation of tumor suppressor genes and activation of a myriad of different oncogenes, DNA mutations, and epigenetic changes. The widely adopted staging of ACC is by European Network of Study of Adrenal Tumors (ENSAT) due to its correlations with clinical outcomes. At the time of presentation, a detailed history taking with attention to the history of symptoms of hormonal excess and family history of possible hereditary influence is the first step of evaluation. It is followed by a thorough physical examination for evaluation of ACC. Management of ACC poses a unique challenge as it involves oncologic and endocrine issues. Except for one trial, treatment guidelines are based on retrospective studies and non-randomized trials, and therefore the level of evidence is grade II to grade IV. Personalized therapy including identifying the actionable target in each patient is the future of ACC management. The knowledge base of ACC is evolving based on the basic science and clinical trials conducted by worldwide groups such as COMITE of France, ENSAT of Europe, TCGA project and American Australian Asian Adrenal Alliance (A5). Future studies should aim at clear molecular and clinical standardization. Recommended therapeutic strategies should be prospectively recorded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.